Title |
Treatment of Pediatric Acute Lymphoblastic Leukemia
|
---|---|
Published in |
Pediatric clinics of North America, October 2014
|
DOI | 10.1016/j.pcl.2014.09.006 |
Pubmed ID | |
Authors |
Stacy L. Cooper, Patrick A. Brown |
Abstract |
Acute lymphoblastic leukemia (ALL) is the most common pediatric oncologic diagnosis, and advances in its treatment have led to progressive improvements in survival. The 4 main components of therapy are remission induction, consolidation, maintenance, and central nervous system-directed therapy, and usually last 2 to 3 years. Treatment intensity based on risk-based stratification is the cornerstone of treatment. Patients with features of more favorable disease are spared the more toxic effects of chemotherapy, whereas more aggressive regimens are reserved for those with higher-risk disease. Prognosis of relapsed pediatric ALL depends primarily on duration of remission and site of relapse. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Comoros | 1 | 50% |
United States | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | <1% |
Bangladesh | 1 | <1% |
Colombia | 1 | <1% |
Spain | 1 | <1% |
Mexico | 1 | <1% |
Unknown | 586 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 102 | 17% |
Student > Master | 101 | 17% |
Researcher | 48 | 8% |
Student > Ph. D. Student | 48 | 8% |
Other | 35 | 6% |
Other | 82 | 14% |
Unknown | 176 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 173 | 29% |
Biochemistry, Genetics and Molecular Biology | 82 | 14% |
Agricultural and Biological Sciences | 42 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 27 | 5% |
Nursing and Health Professions | 25 | 4% |
Other | 54 | 9% |
Unknown | 189 | 32% |